A plethora of developments are occurring in the biotech sphere, especially involving Moderna (NasdaqGS:MRNA). Amidst a high-stakes patent battle, Moderna has witnessed both wins and losses against Pfizer and BioNTech. Despite a predicted drop in revenue, the company’s stock has surprisingly gone up by 10%. An ongoing battle against mRNA vaccines persists in several states, while experts continue to express doubt about COVID-19 vaccine studies that claim mRNA harms. On the other hand, Moderna achieved a legal victory in Düsseldorf against Pfizer and BioNTech which has boosted investor confidence.
However, Moderna’s norovirus vaccine trial is currently on hold by the US FDA due to a neurological side effect reported. Despite these setbacks, Moderna is looking forward to the launch of a cancer vaccine developed in partnership with Merck in 2027. Additionally, the company was awarded $590M by the HHS to develop mRNA vaccines against pandemic flu threats notwithstanding ongoing review and potential withdrawal of funding for the bird flu vaccine. Furthermore, Moderna has started clinical trials for several promising mRNA vaccines.
Moderna MRNA News Analytics from Wed, 12 Jun 2024 07:00:00 GMT to Sat, 08 Mar 2025 10:30:00 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor 5
